Isabelle Ray‐Coquard
0000-0003-2472-8306
Publication & Citation Trends
Publications
1,014 total
Rezatapopt, a selective p53 reactivator, in advanced or metastatic solid tumours with a TP53 Y220C mutation: interim efficacy results from patients with ovarian cancer in the phase 2 PYNNACLE trial
Cited by 0
Semantic Scholar
Subgroup analysis of tumour response by number and type of prior therapy in REJOICE-ovarian01, a phase 2 study of raludotatug deruxtecan (R-dxd) in patients with platinum-resistant ovarian cancer
Cited by 0
Semantic Scholar
Results from the first-in-human phase 1 study of LY4170156, a folate receptor alpha-targeting antibody drug conjugate, in ovarian cancer patients previously exposed to antibody drug conjugate therapy
Cited by 0
Semantic Scholar
Global trends and determinants of HRD and BRCA testing in ovarian cancer management: a cross-sectional study from the european network of young gynaecologic oncologists (ENYGO)
Cited by 0
Semantic Scholar
Assessing gender and regional diversity in ESGO and ENYGO membership and governance: A 12-year perspective
Cited by 0
Semantic Scholar
Prognostic impact of time to first recurrence in low-grade serous ovarian carcinoma: a multicentric retrospective study from the french TMRG network
Cited by 0
Semantic Scholar
Individualized strategies in advanced epithelial ovarian cancer: a multiparametric predictive approach
Cited by 0
Semantic Scholar
Surgical Outcomes In Low-Grade Serous Ovarian Cancer: Comparing Primary Debulking Surgery With Neoadjuvant Chemotherapy
Cited by 0
Semantic Scholar
Research Topics
Ovarian cancer diagnosis and treatment
(460)
PARP inhibition in cancer therapy
(176)
Sarcoma Diagnosis and Treatment
(142)
Uterine Myomas and Treatments
(114)
Endometrial and Cervical Cancer Treatments
(105)
Affiliations
Université Claude Bernard Lyon 1
Délégation Paris 5
Gynecologic Oncology Group
Novartis (Switzerland)
European Organisation for Rare Diseases